<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03296683</url>
  </required_header>
  <id_info>
    <org_study_id>960-CLP-ITL_RI8 _ITS1</org_study_id>
    <nct_id>NCT03296683</nct_id>
  </id_info>
  <brief_title>Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer</brief_title>
  <official_title>Evaluation of a Three Dimensional Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Real Imaging Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Real Imaging Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to evaluate the added value of MIRA technology as an adjunct to
      mammography in the detection of malignant breast lesions in women with dense breast and/or at
      elevated risk of breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in incremental cancer detection rate</measure>
    <time_frame>24 months</time_frame>
    <description>Statistically significant increase of 30% or more in incremental cancer detection rate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>MIRA device imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MIRA Device imaging for adjunctive detection of breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MIRA device imaging</intervention_name>
    <description>MIRA Device imaging for adjunctive detection of breast cancer</description>
    <arm_group_label>MIRA device imaging</arm_group_label>
    <other_name>Real Imager 8</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A - Subjects who are asymptomatic and scheduled to undergo routine screening mammography OR
        B - Subjects scheduled for image guided needle biopsy as a result of findings obtained
        during standard of care imaging modalities (mammography, ultrasound and/or MRI) performed
        at the clinical site that participates in the study.

        Exclusion Criteria:

          1. Male by birth.

          2. Individual is less than 24 years old.

          3. Contraindication to bilateral mammography or MRI.

          4. Subjects who are unable to read, understand and execute the informed consent
             procedure.

          5. Subjects who have had mammography, ultrasound or MRI examination performed on the day
             of the study prior to MIRA scan.

          6. Subjects who have significant existing breast trauma.

          7. Subjects who have undergone lumpectomy/mastectomy.

          8. Subjects who have undergone breast reduction or breast augmentation.

          9. Subjects who have undergone any other type of breast surgery.

         10. Subjects who have large breast scar / Breast deformation.

         11. Subjects who have undergone a breast needle biopsy within the 6 month period prior to
             their intended enrollment into the study.

         12. Subjects who have a temperature &gt; 100Â° F (37.8C) degrees on the day of the MIRA
             imaging.

         13. Subjects who are pregnant or lactating.

         14. Subjects who have had placement of an internal breast marker.

         15. Subjects with known Raynaud's Disease.

         16. Subjects that are claustrophobic or have physical limitations that do allow them to
             sit in the system chair for the required imaging session.

         17. Subjects with implanted pacemaker/defibrillator, implanted venous access device
             (portacath) or other implanted devices.

         18. Subjects with a BI-RADS category 6 (e.g. for which mammogram was performed for the
             purpose of planning cancer therapy).

         19. Subjects affected with epilepsy.

         20. Subjects who participated in the Calibration Phase will not be able to participate in
             the Testing Phase.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Sardanelli, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico San Donato</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Izhaky</last_name>
    <phone>+972-3-972-0602</phone>
    <email>david@realimaging.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Sardanelli, M.D.</last_name>
      <phone>39-02-52774468</phone>
      <email>f.sardanelli@grupposandonato.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2017</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

